Lupin launches generic Ravicti in U.S. market

Global pharmaceutical leader Lupin Limited announced on October 24, 2025, the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. This product is indicated for the chronic management of urea cycle disorders (UCDs) in patients who cannot be effectively managed through dietary protein restriction or amino acid supplementation alone.

Lupin, headquartered in Mumbai, India, distributes products across more than 100 markets. The company specializes in various pharmaceutical products, including branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and 7 research centers globally, supported by a workforce of over 24,000 professionals.

This launch reinforces Lupin's commitment to improving patient health outcomes, leveraging its extensive global presence and diverse therapeutic areas, which include respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.